Droxicam

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H11N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F24ADO1E2D, chemically known as 5-methyl-3-(2-pyridyl)-2h,5h-1,3-oxazino(5,6-c)(1,2)benzothiazine-2,4(3h)-dione 6,6-dioxide but generally known as droxicam, which bears US NIH Compound Identifier 65679. European Medicines Agency schedules Droxicam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06419MIG. The term DROXICAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules droxicam in its Anatomical Therapeutic Chemical (ATC) Classification. DROXICAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule droxicam under HS 29349990 and SITC 51579. As of Q4 2014, DROXICAM remains the US FDA Preferred Term for this commodity. Droxicam bears US NLM identifiers UMLS ID C0058765 and NCI Concept Code C65492. SMILES: S1(=O)(=O)N(C2C(OC(=O)N(C2=O)C2NCCCC2)C2C1CCCC2)C.